Targeting EGFR signalling pathway in triple negative breast cancer
<p>Epidermal growth factor receptor (EGFR) is frequently overexpressed in the majority of triple negative breast cancer patients (TNBC). However, the molecular determinants behind their limited response to EGFR-targeted therapies are poorly understood. Here, both the acute and chronic response...
Príomhchruthaitheoir: | |
---|---|
Rannpháirtithe: | |
Formáid: | Tráchtas |
Teanga: | English |
Foilsithe / Cruthaithe: |
2014
|
Ábhair: |